Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalizations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

Eric J HaasFrederick J AnguloJohn M McLaughlinEmilia AnisShepherd R SingerFarid KhanNati BrooksMeir SmajaGabriel MircusKaijie PanJo SouthernDavid L SwerdlowLuis JodarYeheskel LevySharon Alroy-PreisAuthors:

During the analysis period (Jan 24 to April 3, 2021), there were 232 268 SARS-CoV-2 infections, 7694 COVID-19 hospitalizations, 4481 severe or critical COVID-19 hospitalizations, and 1113 COVID-19 deaths in people aged 16 years or older. By April 3, 2021, 4 714 932 (72∙1%) of 6 538 911 people aged 16 years and older were fully vaccinated with two doses of BNT162b2. Adjusted estimates of vaccine effectiveness at 7 days or longer after the second dose were 95∙3% (95% CI 94∙9–95∙7; incidence rate 91∙5 per 100 000 person-days in unvaccinated vs 3·1 per 100 000 person-days in fully vaccinated individuals) against SARS-CoV-2 infection, 91∙5% (90∙7–92∙2; 40∙9 vs 1∙8 per 100 000 person-days) against asymptomatic SARS-CoV-2 infection, 97∙0% (96∙7–97∙2; 32∙5 vs 0∙8 per 100 000 person-days) against symptomatic COVID-19, 97∙2% (96∙8–97∙5; 4∙6 vs 0∙3 per 100 000 person-days) against COVID-19-related hospitalization, 97∙5% (97∙1–97∙8; 2∙7 vs 0∙2 per 100 000 person-days) against severe or critical COVID-19-related hospitalization, and 96∙7% (96∙0–97∙3; 0·6 vs 0·1 per 100 000 person-days) against COVID-19-related death. In all age groups, as vaccine coverage increased, the incidence of SARS-CoV-2 outcomes declined. 8006 of 8472 samples tested showed a spike gene target failure, giving an estimated prevalence of the B.1.1.7 variant of 94∙5% among SARS-CoV-2 infections.

https://reader.elsevier.com/reader/sd/pii/S0140673621009478?token=F5B0E3DDB6C03ED95F9BBAEE36DCE7AC23C216839C52E8FDD75B273982F687FB0505E0D1860DA0F1567C5BBBA7A244A9&originRegion=us-east-1&originCreation=20211123161326

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

Authors: Sara YTartofPhDaeJeff MSlezakMSaHeidiFischerPhDaVennisHongMPHaBradley KAckersonMDbOmesh NRanasingheMPHaTimothy BFranklandMAcOluwaseye AOgunMDaJoann MZamparoMPHdSharonGrayMSdSrinivas RValluriPhDdKaijePanMSdFrederick JAnguloPhDdLuisJodarPhDdJohn MMcLaughlinPhDd

Between Dec 14, 2020, and Aug 8, 2021, of 4 920 549 individuals assessed for eligibility, we included 3 436 957 (median age 45 years [IQR 29–61]; 1 799 395 [52·4%] female and 1 637 394 [47·6%] male). For fully vaccinated individuals, effectiveness against SARS-CoV-2 infections was 73% (95% CI 72–74) and against COVID-19-related hospital admissions was 90% (89–92). Effectiveness against infections declined from 88% (95% CI 86–89) during the first month after full vaccination to 47% (43–51) after 5 months. Among sequenced infections, vaccine effectiveness against infections of the delta variant was high during the first month after full vaccination (93% [95% CI 85–97]) but declined to 53% [39–65] after 4 months. Effectiveness against other (non-delta) variants the first month after full vaccination was also high at 97% (95% CI 95–99), but waned to 67% (45–80) at 4–5 months. Vaccine effectiveness against hospital admissions for infections with the delta variant for all ages was high overall (93% [95% CI 84–96]) up to 6 months.

https://www.sciencedirect.com/science/article/pii/S0140673621021838